Soluble Flt-1 links microvascular disease with heart failure in CKD

Basic Research in Cardiology

Volumn 110, Issue 3, 2015, Pages

  Di Marco, Giovana S ^a   Kentrup, Dominik ^a   Reuter, Stefan ^a   Mayer, Anna B ^a   Golle, Lina ^a   Tiemann, Klaus ^b   Fobker, Manfred ^a   Engelbertz, Christiane ^a   Breithardt, Günter ^a   Brand, Eva ^a   Reinecke, Holger ^a   Pavenstädt, Hermann ^a   Brand, Marcus ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Isar Heart Center   (Germany)

Author keywords

Chronic kidney disease; Heart failure; Microcirculation; sFlt 1

Indexed keywords

VASCULOTROPIN 121; VASCULOTROPIN RECEPTOR 1; FLT1 PROTEIN, HUMAN; FLT1 PROTEIN, RAT;

AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VOLUME; CAPILLARY DENSITY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MITOCHONDRION; HEART MUSCLE FIBROSIS; HEART OUTPUT; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VASCULAR REMODELING; ANIMAL; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; MICROVASCULATURE; PATHOLOGY;

ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMANS; MALE; MICROVESSELS; RATS; RENAL INSUFFICIENCY, CHRONIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84938336303     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-015-0487-4     Document Type: Article

References (55)

1. Amann K, Ritz E (2000) Microvascular disease—the Cinderella of uraemic heart disease. Nephrol Dial Transplant 15:1493–1503. doi:10.1093/ndt/15.10.1493
2. Bellamy L, Casas JP, Hingorani AD, Williams DJ (2007) Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 335:974. doi:10.1136/bmj.39335.385301.BE
3. Bencini PL, Montagnino G, Citterio A, Graziani G, Crosti C, Ponticelli C (1985) Cutaneous abnormalities in uremic patients. Nephron 40:316–321
4. Bergmann A, Ahmad S, Cudmore M, Gruber AD, Wittschen P, Lindenmaier W, Christofori G, Gross V, Gonzalves AC, Grone HJ, Ahmed A, Weich HA (2010) Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 14:1857–1867. doi:10.1111/j.1582-4934.2009.00820.x
5. Brand E, Pavenstadt H, Schmieder RE, Engelbertz C, Fobker M, Pinnschmidt HO, Wegscheider K, Breithardt G, Reinecke H (2013) The Coronary Artery Disease and Renal Failure (CAD-REF) registry: trial design, methods, and aims. Am Heart J 166:449–456. doi:10.1016/j.ahj.2013.06.010
6. Bridges JP, Gilbert JS, Colson D, Gilbert SA, Dukes MP, Ryan MJ, Granger JP (2009) Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertens 22:564–568. doi:10.1038/ajh.2009.24
7. Cabiati M, Campan M, Caselli C, Prescimone T, Giannessi D, Del RS (2010) Sequencing and cardiac expression of natriuretic peptide receptors A and C in normal and heart failure pigs. Regul Pept 162:12–17. doi:10.1016/j.regpep.2010.02.004
8. Cindrova-Davies T, Sanders DA, Burton GJ, Charnock-Jones DS (2011) Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovasc Res 89:671–679. doi:10.1093/cvr/cvq346
9. Currie G, Delles C (2013) Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis 7:13–24. doi:10.2147/IJNRD.S40522
10. De Boer RA, Pinto YM, Van Veldhuisen DJ (2003) The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 10:113–126. doi:10.1038/sj.mn.7800188
11. Del RS, Andreassi MG, Clerico A, Biagini A, Giannessi D (2001) Endothelin-1, endothelin-1 receptors and cardiac natriuretic peptides in failing human heart. Life Sci 68:2715–2730
12. Di Marco GS, Reuter S, Hillebrand U, Amler S, Konig M, Larger E, Oberleithner H, Brand E, Pavenstadt H, Brand M (2009) The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 20:2235–2245. doi:10.1681/ASN.2009010061
13. Di Marco GS, Reuter S, Kentrup D, Ting L, Ting L, Grabner A, Jacobi AM, Pavenstadt H, Baba HA, Tiemann K, Brand M (2011) Cardioprotective effect of calcineurin inhibition in an animal model of renal disease. Eur Heart J 32:1935–1945. doi:10.1093/eurheartj/ehq436
14. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382:339–352. doi:10.1016/S0140-6736(13)60595-4
15. Gavin JB, Maxwell L, Edgar SG (1998) Microvascular involvement in cardiac pathology. J Mol Cell Cardiol 30:2531–2540. doi:10.1006/jmcc.1998.0824
16. Giordano FJ, Gerber HP, Williams SP, VanBruggen N, Bunting S, Ruiz-Lozano P, Gu Y, Nath AK, Huang Y, Hickey R, Dalton N, Peterson KL, Ross J Jr, Chien KR, Ferrara N (2001) A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci USA 98:5780–5785. doi:10.1073/pnas.091415198
17. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305. doi:10.1056/NEJMoa041031
18. Gordon O, Gilon D, He Z, May D, Lazarus A, Oppenheim A, Keshet E (2012) Vascular endothelial growth factor-induced neovascularization rescues cardiac function but not adverse remodeling at advanced ischemic heart disease. Arterioscler Thromb Vasc Biol 32:1642–1651. doi:10.1161/ATVBAHA.112.248674
19. Guo Q, Carrero JJ, Yu X, Barany P, Qureshi AR, Eriksson M, Anderstam B, Chmielewski M, Heimburger O, Stenvinkel P, Lindholm B, Axelsson J (2009) Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients. Nephrol Dial Transplant 24:3468–3473. doi:10.1093/ndt/gfp315
20. Hara A, Wada T, Furuichi K, Sakai N, Kawachi H, Shimizu F, Shibuya M, Matsushima K, Yokoyama H, Egashira K, Kaneko S (2006) Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int 69:1986–1995. doi:10.1038/sj.ki.5000439
21. Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589–600. doi:10.1038/nrm1983
22. Hilfiker-Kleiner D, Limbourg A, Drexler H (2005) STAT3-mediated activation of myocardial capillary growth. Trends Cardiovasc Med 15:152–157. doi:10.1016/j.tcm.2005.05.002
23. Hochholzer W, Reichlin T, Stelzig C, Hochholzer K, Meissner J, Breidthardt T, Reiter M, Duehsler B, Freidank H, Winkler K, Twerenbold R, Mueller C (2011) Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction. Eur Heart J 32:326–335. doi:10.1093/eurheartj/ehq429
24. Jacobi J, Porst M, Cordasic N, Namer B, Schmieder RE, Eckardt KU, Hilgers KF (2006) Subtotal nephrectomy impairs ischemia-induced angiogenesis and hindlimb re-perfusion in rats. Kidney Int 69:2013–2021. doi:10.1038/sj.ki.5000448
25. Kendall RL, Wang G, Thomas KA (1996) Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226:324–328. doi:10.1006/bbrc.1996.1355
26. Kendrick J, Chonchol MB (2008) Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 4:672–681. doi:10.1038/ncpneph0954
27. Kim SY, Lee SH, Park S, Kang SM, Chung N, Shim WH, Cho SY, Sun HJ, Manabe I, Jang Y (2011) Vascular endothelial growth factor, soluble fms-like tyrosine kinase 1, and the severity of coronary artery disease. Angiology 62:176–183. doi:10.1177/0003319710370963
28. Kitzman DW, Upadhya B, Vasu S (2015) What the dead can teach the living: systemic nature of heart failure with preserved ejection fraction. Circulation 131:522–524. doi:10.1161/CIRCULATIONAHA.114.014420
29. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J (2007) Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 18:1307–1315. doi:10.1681/ASN.2006101159
30. Ky B, French B, Ruparel K, Sweitzer NK, Fang JC, Levy WC, Sawyer DB, Cappola TP (2011) The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure. J Am Coll Cardiol 58:386–394. doi:10.1016/j.jacc.2011.03.032
31. Lavainne F, Meffray E, Pepper RJ, Neel M, Delcroix C, Salama AD, Fakhouri F (2014) Heparin use during dialysis sessions induces an increase in the antiangiogenic factor soluble Flt1. Nephrol Dial Transplant 29:1225–1231. doi:10.1093/ndt/gft517
32. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683. doi:10.1056/NEJMoa031884
33. Levy AP (1999) A cellular paradigm for the failure to increase vascular endothelial growth factor in chronically hypoxic states. Coron Artery Dis 10:427–430
34. Li F, Hagaman JR, Kim HS, Maeda N, Jennette JC, Faber JE, Karumanchi SA, Smithies O, Takahashi N (2012) eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype. J Am Soc Nephrol 23:652–660. doi:10.1681/ASN.2011040369
35. Luttun A, Carmeliet P (2003) Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest 111:600–602
36. Matsui M, Takeda Y, Uemura S, Matsumoto T, Seno A, Onoue K, Tsushima H, Morimoto K, Soeda T, Okayama S, Somekawa S, Samejima KI, Kawata H, Kawakami R, Nakatani K, Iwano M, Saito Y (2013) Suppressed soluble Fms-like tyrosine kinase-1 production aggravates atherosclerosis in chronic kidney disease. Kidney Int 85:393–403. doi:10.1038/ki.2013.339
37. May D, Gilon D, Djonov V, Itin A, Lazarus A, Gordon O, Rosenberger C, Keshet E (2008) Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci USA 105:282–287. doi:10.1073/pnas.0707778105
38. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649–658. doi:10.1172/JCI17189
39. Murphy SR, LaMarca B, Cockrell K, Arany M, Granger JP (2012) L-arginine supplementation abolishes the blood pressure and endothelin response to chronic increases in plasma sFlt-1 in pregnant rats. Am J Physiol Regul Integr Comp Physiol 302:R259–R263. doi:10.1152/ajpregu.00319.2011
40. Muttukrishna S, Swer M, Suri S, Jamil A, Calleja-Agius J, Gangooly S, Ludlow H, Jurkovic D, Jauniaux E (2011) Soluble Flt-1 and PlGF: new markers of early pregnancy loss? PLoS One 6:e18041. doi:10.1371/journal.pone.0018041
41. Neubauer S (2007) The failing heart—an engine out of fuel. N Engl J Med 356:1140–1151. doi:10.1056/NEJMra063052
42. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9–22
43. O’Riordan E, Chen J, Brodsky SV, Smirnova I, Li H, Goligorsky MS (2005) Endothelial cell dysfunction: the syndrome in making. Kidney Int 67:1654–1658. doi:10.1111/j.1523-1755.2005.00256.x
44. Onoue K, Uemura S, Takeda Y, Somekawa S, Iwama H, Nishida T, Morikawa Y, Nakagawa H, Tsutsumi T, Sung JH, Takemoto Y, Soeda T, Okayama S, Ishigami K, Kawata H, Horii M, Nakajima T, Saito Y (2009) Usefulness of soluble Fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction. Am J Cardiol 104:1478–1483. doi:10.1016/j.amjcard.2009.07.016
45. Parodi EM, Kuhn B (2014) Signalling between microvascular endothelium and cardiomyocytes through neuregulin. Cardiovasc Res 102:194–204. doi:10.1093/cvr/cvu021
46. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, Hacker MR, Rhee JS, Mitchell J, Mahmood F, Hess P, Farrell C, Koulisis N, Khankin EV, Burke SD, Tudorache I, Bauersachs J, del MF, Hilfiker-Kleiner D, Karumanchi SA, Arany Z (2012) Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485:333–338. doi:10.1038/nature11040
47. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA, Thadhani R, Wolf M, Harger G, Markovic N (2005) Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 26:563–573. doi:10.1016/j.placenta.2004.09.001
48. Ramaciotti C, Sharkey A, McClellan G, Winegrad S (1992) Endothelial cells regulate cardiac contractility. Proc Natl Acad Sci USA 89:4033–4036
49. Sattar N, Greer IA (2002) Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ 325:157–160. doi:10.1136/bmj.325.7356.157
50. Searle J, Slagman A, Gwosc S, Vollert JO, Holert F, Muller C, Muller R, Mockel M (2012) Soluble fms-like tyrosine kinase-1 (sFLT-1) predicts post-percutaneous coronary intervention (PCI) myocardial infarction (MI type 4a). Biomarkers 17:730–737. doi:10.3109/1354750X.2012.725428
51. Smith DH, Thorp ML, Gurwitz JH, McManus DD, Goldberg RJ, Allen LA, Hsu G, Sung SH, Magid DJ, Go AS (2013) Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study. Circ Cardiovasc Qual Outcomes 6:333–342. doi:10.1161/CIRCOUTCOMES.113.000221
52. Thang OH, Serne EH, Grooteman MP, Smulders YM, ter Wee PM, Tangelder GJ, Nube MJ (2011) Capillary rarefaction in advanced chronic kidney disease is associated with high phosphorus and bicarbonate levels. Nephrol Dial Transplant 26:3529–3536. doi:10.1093/ndt/gfr089
53. Ventura-Clapier R, Garnier A, Veksler V, Joubert F (2011) Bioenergetics of the failing heart. Biochim Biophys Acta 1813:1360–1372. doi:10.1016/j.bbamcr.2010.09.006
54. Vorovich E, French B, Ky B, Goldberg L, Fang JC, Sweitzer NK, Cappola TP (2014) Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis. J Card Fail 20:569–576. doi:10.1016/j.cardfail.2014.05.013
55. Widyantoro B, Emoto N, Nakayama K, Anggrahini DW, Adiarto S, Iwasa N, Yagi K, Miyagawa K, Rikitake Y, Suzuki T, Kisanuki YY, Yanagisawa M, Hirata K (2010) Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 121:2407–2418. doi:10.1161/CIRCULATIONAHA.110.938217